My guess is the cap raising has left a few people unhappy and they're moving on. Volume doesn't look massive but it does point to a dearth of buyers.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
AXN Rising demand, China's 'tech war' bans leaves this germanium explorer with significant investment potential
